Home>Topics>Stocks>Myriad Genetics

Myriad Genetics MYGN

  1. All
  2. Commentary
  3. Headlines
    1. Myriad's Reimbursement Woes Continue


      Wed, 6 May 2015

      Myriad Genetics reported third-quarter earnings that fell slightly behind our expectations due to harsh weather on the East Coast and some seasonal

    2. MyRisk Orders Continue to Strain Myriad's Lab Capacity


      Wed, 4 Feb 2015

      Myriad Genetics posted weak second-quarter results as myRisk orders continued to increase lab turnaround time and weigh on margins. The company

    3. Leader in Genomic Sequencing Illuminates the Way


      Wed, 14 Jan 2015

      price-competitive. Illumina and numerous others, including other test manufacturers like Qiagen QGEN and test providers like Myriad MYGN , have announced development plans for gene panel tests to evaluate baskets of specific biomarkers. There are too many unknown

    4. Increased MyRisk Turnaround Weighs on Myriad’s First-quarter Results


      Wed, 5 Nov 2014

      Myriad Genetics reported first-quarter results that were in line with its recent warning that a hike in orders for myRisk are increasing lab turnaround

    5. Myriad Encounters Minor Snag With MyRisk, Announces Positive Prolaris News


      Fri, 17 Oct 2014

      In conjunction with positive Prolaris news, Myriad Genetics announced that it is receiving myRisk samples more rapidly than anticipated, and that the subsequent increase in costs and turnaround

    6. Initial Uptake of Myriad's MyRisk Panel Test Remains Encouraging


      Wed, 13 Aug 2014

      Myriad Genetics reported fourth-quarter earnings Tuesday that were largely in line with our expectations as growth saw headwinds from revised

    7. Stock Picking Matters in the Current Market Climate


      Thu, 26 Jun 2014

      confident about right now? I discussed Myriad Genetics in January, and I still really like ..... portfolios for more than a decade. Like Myriad Genetics , its share price has been somewhat ..... 0.00 0.00 0.00 1.32 0.00 Myriad Genetics 3.18 1.90 3.56 4.02 0.00

    8. Myriad's Private Pricing Proves Durable in Third Fiscal Quarter


      Wed, 7 May 2014

      Myriad Genetics reported third-quarter earnings on Tuesday that were largely in line with our expectations, as private-payer pricing remained

    9. Chip Skinner on 1Q14: Looking at Current Long-Term Growth Plays


      Thu, 10 Apr 2014

      detractor in Value Plus, I’ve been very happy to see Myriad Genetics rebound nicely in 2014. Myriad is a molecular diagnostic ..... 31/13 (%) RVP RLP Rockwood Holdings 1.77 0.00 Myriad Genetics 1.58 1.88 There can be no assurance that any of the

    10. CMS Restores BRACAnalysis Reimbursement


      Wed, 2 Apr 2014

      a surprising turn of events, the Centers for Medicare and Medicaid Services have posted a 52% increase in pricing for Myriad Genetics ’ BRACAnalysis test, from $1,438 to $2,184. As such, we plan to significantly raise our fair value estimate by

    « Prev12345Next »
    Content Partners